Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria.

Literature DB >> 4782059

Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria.

S Kondo, K Iinuma, H Yamamoto, K Maeda, H Umezawa.

Abstract

Mesh：

Substances：

Year: 1973 PMID： 4782059 DOI： 10.7164/antibiotics.26.412

Source DB: PubMed Journal: J Antibiot (Tokyo) ISSN： 0021-8820 Impact factor: 2.649

Keyword Cloud
Cited

× No keyword cloud information.

19 in total

Review 1. Aminoglycosides: activity and resistance.

Authors: M P Mingeot-Leclercq; Y Glupczynski; P M Tulkens
Journal: Antimicrob Agents Chemother Date: 1999-04 Impact factor: 5.191

2. Euvesperins A and B, new circumventors of arbekacin resistance in MRSA, produced by Metarhizium sp. FKI-7236.

Authors: Mayu Shiina; Takuya Suga; Yukihiro Asami; Kenichi Nonaka; Masato Iwatsuki; Satoshi Omura; Kazuro Shiomi
Journal: J Antibiot (Tokyo) Date: 2016-01-13 Impact factor: 2.649

3. Discovery of 2-hydroxyarbekacin, a new aminoglycoside antibiotic with reduced nephrotoxicity.

Authors: Yoshiaki Takahashi; Eijiro Umemura; Yoshihiko Kobayashi; Shoichi Murakami; Toru Nawa; Akihiro Morinaka; Toshiaki Miyake; Masakatsu Shibasaki
Journal: J Antibiot (Tokyo) Date: 2017-06-28 Impact factor: 2.649

4. Synthesis and antibacterial activity of 4″ or 6″-alkanoylamino derivatives of arbekacin.

Authors: Kazushige Sasaki; Yoshihiko Kobayashi; Takashi Kurihara; Yohei Yamashita; Yoshiaki Takahashi; Toshiaki Miyake; Yuzuru Akamatsu
Journal: J Antibiot (Tokyo) Date: 2015-05-20 Impact factor: 2.649

5. Paraphaeosphaeride D and berkleasmin F, new circumventors of arbekacin resistance in MRSA, produced by Paraphaeosphaeria sp. TR-022.

Authors: Takuya Suga; Mayu Shiina; Yukihiro Asami; Masato Iwatsuki; Tsuyoshi Yamamoto; Kenichi Nonaka; Rokuro Masuma; Hidehito Matsui; Hideaki Hanaki; Susumu Iwamoto; Hideyuki Onodera; Kazuro Shiomi; Satoshi Ōmura
Journal: J Antibiot (Tokyo) Date: 2016-06-22 Impact factor: 2.649

6. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

Authors: Reiko Sato; Yusuke Tanigawara; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal: Antimicrob Agents Chemother Date: 2006-11 Impact factor: 5.191

Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria.

Review 1. Aminoglycosides: activity and resistance.

2. Euvesperins A and B, new circumventors of arbekacin resistance in MRSA, produced by Metarhizium sp. FKI-7236.

3. Discovery of 2-hydroxyarbekacin, a new aminoglycoside antibiotic with reduced nephrotoxicity.

4. Synthesis and antibacterial activity of 4″ or 6″-alkanoylamino derivatives of arbekacin.

5. Paraphaeosphaeride D and berkleasmin F, new circumventors of arbekacin resistance in MRSA, produced by Paraphaeosphaeria sp. TR-022.

6. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

7. Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus.

Review 8. Aminoglycoside research 1975-1985: prospects for development of improved agents.

9. Mechanism of action of habekacin, a novel amino acid-containing aminoglycoside antibiotic.

10. Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.